Harrow (NASDAQ:HROW) Shares Gap Up - Time to Buy?

Harrow, Inc. (NASDAQ:HROW - Get Free Report) shares gapped up before the market opened on Tuesday . The stock had previously closed at $30.15, but opened at $30.99. Harrow shares last traded at $30.60, with a volume of 113,110 shares trading hands.

Wall Street Analyst Weigh In

HROW has been the subject of several analyst reports. William Blair initiated coverage on shares of Harrow in a report on Tuesday. They set an "outperform" rating for the company. BTIG Research initiated coverage on shares of Harrow in a report on Thursday. They set a "buy" rating and a $62.00 price target for the company. HC Wainwright boosted their price target on shares of Harrow from $57.00 to $60.00 and gave the company a "buy" rating in a report on Monday, May 12th. Finally, B. Riley reduced their price target on shares of Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, Harrow presently has a consensus rating of "Buy" and an average target price of $61.40.

Harrow Stock Down 2.7%

The firm has a market cap of $1.11 billion, a price-to-earnings ratio of -32.24 and a beta of 0.40. The firm's fifty day moving average is $26.16 and its two-hundred day moving average is $29.69. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44.

Harrow (NASDAQ:HROW - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.40). The company had revenue of $47.83 million during the quarter, compared to analyst estimates of $57.00 million. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. On average, sell-side analysts expect that Harrow, Inc. will post -0.53 EPS for the current fiscal year.

Institutional Investors Weigh In On Harrow

Several institutional investors have recently bought and sold shares of the stock. Woodmont Investment Counsel LLC lifted its holdings in Harrow by 0.5% in the fourth quarter. Woodmont Investment Counsel LLC now owns 81,400 shares of the company's stock worth $2,731,000 after purchasing an additional 445 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Harrow by 3.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,356 shares of the company's stock valued at $582,000 after acquiring an additional 585 shares during the last quarter. Swiss National Bank lifted its holdings in Harrow by 1.0% in the 4th quarter. Swiss National Bank now owns 59,300 shares of the company's stock valued at $1,990,000 after acquiring an additional 600 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in Harrow in the 4th quarter valued at about $25,000. Finally, MetLife Investment Management LLC lifted its holdings in Harrow by 5.7% in the 4th quarter. MetLife Investment Management LLC now owns 18,908 shares of the company's stock valued at $634,000 after acquiring an additional 1,026 shares during the last quarter. Institutional investors and hedge funds own 72.76% of the company's stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.